Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02265952 · ClinicalTrials.gov registry record · Phase 2
Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
A Phase 2 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02265952 is a Phase 2 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT02265952, a Phase 2 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is an open-label, single-arm study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by REGN1500 in patients with homozygous familial hypercholesterolemia (HoFH).
Interventions
- DRUG REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-02-04 |
| Est. Completion | 2018-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02265952
The ClinicalTrials.gov registry entry for NCT02265952 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which REGN1500 250 mg SC/15 mg/kg IV/450 mg SC is the first listed.
NCT02265952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02265952 about?
NCT02265952 is a clinical study titled "Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)". This is an open-label, single-arm study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by REGN1500 in patients with homozygous familial hypercholesterolemia (HoFH).
What is the current status of trial NCT02265952?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2015-02-04. Estimated completion is 2018-07-23.
What interventions are being tested in trial NCT02265952?
The interventions under investigation include: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC (DRUG).
Who is sponsoring clinical trial NCT02265952?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.